Skip to main content
1-featuredimage

Welcome to hubXchange's Antibody Therapeutics Xchange San Francisco 2026.

This event brings together senior-level scientists and executives from the pharmaceutical and biotech sectors to tackle key challenges in Target Selection & Mechanisms of Action, Lead Identification & Optimization, Formats & ScaffoldsBi/MultispecificsADC Linker Design & Conjugation Technologies, and ADC Cytotoxic Payload

Attendees can engage in roundtable discussions, pre-booked 1:1 meetingspresentations, and networking sessions with top industry experts, to foster collaboration and find innovative solutions to accelerate antibody therapeutics.

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking.

San Francisco | Wednesday 2nd September 2026 | 08:00am - 06:10pm

 VIEW AGENDA    REGISTER FOR FREE    OUR PARTNERS    EVENT INFORMATION

Why choose hubXchange?

 

FULL AGENDA

Click the topic titles to find out more!

Loading
08:00
  1. Registration
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
08:30
  1. Opening Address & Keynote Presentation: 100+ Undruggable Targets Unlocked Through Parallel MAb Engineering
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Many high-value membrane protein targets, including GPCRs and ion channels, have remained untapped for therapeutic development due to technical barriers such as sequence conservation and structural co ...
09:05
  1. Target Selection & Mechanisms of Action
    60 mins
    • Target Selection & Mechanisms of Action
    How can AI facilitate target discovery and validation? Is target validation still rate-limiting? How to choose the targets and appropriate modalities for developing multi-specific therapeutics?
  2. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
    Why many “best-in-class” binders still fail clinically The industry shift from affinity optimization toward systems-level biology and tissue selectivity Whether potency obsession has created blind spo ...
  3. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
    How should we select targets to improve specificity or increase the addressable population? What is the goal of the multispecific: are we looking for synergy, additive effects, or overcoming resistanc ...
  4. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    Which therapeutic area do you believe multi-specific formats will genuinely transform over the next five years, and what needs to be true scientifically or technically for that to happen? Where do mul ...
  5. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    Can "unclean" targets be opened up through AND-gating? Can OR-gating address tumor heterogeneity? Can poor-internalizing targets be opened up via bispecifics? How should linker and DAR selection chang ...
  6. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    Why do some ADCs achieve significant efficacy with manageable toxicity while others fail despite targeting the same antigen? Which characteristics of target, antibody, linker, payload, and patient bio ...
10:10
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
10:45
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:15
  1. Morning Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
11:25
  1. Target Selection & Mechanisms of Action
    60 mins
    • Target Selection & Mechanisms of Action

    Vizgen

  2. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization

    Mosaic Biosciences

  3. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds

    Nona Biosciences

  4. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics

    FUJIFILM Biosciences

  5. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies

    IQVIA

  6. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
12:25
  1. Networking Lunch
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
13:25
  1. Spotlight Presentation: Advanced Analytical Solutions for Antibodies: Product and Impurity Characterization
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Antibody-based therapeutics generated with current technologies inherently exhibit product heterogeneity due to modifications occurring throughout production. Comprehensive characterization is therefo ...
14:00
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
14:30
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
15:00
  1. Afternoon Refreshments
    10 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
15:10
  1. Spotlight Presentation: Accelerating Antibody and Biologic Workflows with Chemically Aware Macromolecule Registration
    30 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
15:45
  1. Target Selection & Mechanisms of Action
    20 mins
    • Target Selection & Mechanisms of Action
    Traditional drug discovery is heavily bottlenecked by the slow, iterative process of translating disease insights into viable therapeutic candidates. Here, we are introducing an end-to-end computation ...

    Nostrum Bio

  2. Lead Identification & Optimization
    20 mins
    • Lead Identification & Optimization
    The SpyCatcher-SpyTag reaction is a fast, specific method to covalently link two proteins. We developed SpyLock - a 'lockable' SpyCatcher that can be reversibly inhibited to control ligation with a Sp ...

    Bio-Rad

  3. Formats & Scaffolds
    20 mins
    • Formats & Scaffolds

    AbKyu

  4. Bi/Multispecifics
    20 mins
    • Bi/Multispecifics
  5. ADC Linker Design & Conjugation Technologies
    20 mins
    • ADC Linker Design & Conjugation Technologies
    AI-driven protein and antibody design platforms can rapidly generate large candidate sets, but timely experimental data remains a key limitation for effective lead identification and optimization. Her ...

    GenScript

  6. ADC Cytotoxic Payload
    20 mins
    • ADC Cytotoxic Payload
16:10
  1. Lead Identification & Optimization
    60 mins
    • Lead Identification & Optimization
  2. Formats & Scaffolds
    60 mins
    • Formats & Scaffolds
  3. Bi/Multispecifics
    60 mins
    • Bi/Multispecifics
    What has CAR-T already taught us about the biology of durable responses in autoimmune diseases beyond oncology? Can T cell engagers reproduce the key benefits of CAR-T while improving control, access, ...
  4. ADC Linker Design & Conjugation Technologies
    60 mins
    • ADC Linker Design & Conjugation Technologies
    How much of ADC linker selection is rational design versus platform default, and how rigorously are linker choices tested against alternatives? Are we over-indexing on linker chemistry rather than the ...
  5. ADC Cytotoxic Payload
    60 mins
    • ADC Cytotoxic Payload
    Are topoisomerase I inhibitor (TOP1i) payloads the default for solid tumor ADCs, or is the field over-converging on a single payload class with shared toxicity, resistance, and sequencing liabilities? ...
17:10
  1. Drinks-Canape Reception
    60 mins
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization

EVENT INFORMATION

3-featuredimage

DATES

San Francisco
Sept 2, 2026

Wednesday 2nd September 2026

 

DoubleTree by Hilton San Francisco Airport Hotel Photo

 

VENUE

 

DoubleTree by Hilton San Francisco Airport Hotel

DoubleTree by Hilton
San Francisco Airport Hotel
835 Airport Blvd, Burlingame
California, 94010-9949

MAP

EVENT PARTNERS

4-featuredimage

EVENT PARTNERS

OUR MEDIA PARTNERS

5-featuredimage

REGISTRATION FORM - Register for free!

6-featuredimage

Complimentary Registration is only available for Senior Scientists & above, in Pharma & Bio Tech, with an active drug pipeline.
 

For Service Providers, please click here.